PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment
Phospholipase A2 (PLA2) designates a large and diverse
group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
Alle Nachrichten aus der Kategorie: Technology Offerings
Neueste Beiträge
Simplified method to modify disease signaling with light
Most diseases are caused by aberrant cell signaling processes and basic research in cell signaling is needed to identify targets for future therapeutic approaches, especially in cases where no cures…
Highly selective membranes
Researchers discover how water can affect its own filtration. Membranes with microscopic pores are useful for water filtration. The effect of pore size on water filtration is well-understood, as is…
Interactions within larger social groups can cause tipping points in contagion flow
The distribution of group interactions in a social network affects the critical point at which explosive jumps in opinion, popularity, or disease spread occur. Contagion processes, such as opinion formation…